Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

http://www.wikidata.org/entity/Q54268700

about

A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India The case for reactive mass oral cholera vaccinations Critical analysis of compositions and protective efficacies of oral killed cholera vaccines Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response Cholera in India: an analysis of reports, 1997-2006 Killed oral cholera vaccines: history, development and implementation challenges Vibrio cholerae: lessons for mucosal vaccine design.Oral vaccination: where we are?Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity.Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.Preparation and immunogenicity of conjugate based on hydrazine-treated lipopolysaccharide antigen of Vibrio cholerae O139.A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit Needle-free vaccine delivery.Genomic correlates of variability in immune response to an oral cholera vaccine.Establishment of an adult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.New-generation vaccines against cholera.Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings.Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model.Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.Causes of impaired oral vaccine efficacy in developing countries.Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.Cholera The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial

P2860

Q21144301-CA85892A-5A84-4AE5-A55F-905BA9EC46A4 Q21144515-5F595296-0B42-4420-8ECE-D4ABB3AA5EB5 Q26823170-654A6C00-BEA9-4072-AC38-141A34543E00 Q27004488-2FE735DD-8FD3-48DF-ADE0-5D83F24ADA16 Q28384852-00153C1A-5503-4710-B1E8-D9CE1D270CB3 Q30496874-0F429291-22A6-423A-8C1A-B1DDBFFA316F Q33572955-DBD80391-FD88-44E8-AA00-74FFA96CDB83 Q33578033-95FD3957-761A-481A-9C61-B45F0568DC2B Q33588522-4A9BFB55-BD8E-4055-8F7C-6382F69606E0 Q33606727-170023A2-9E03-410B-82E1-B81EA07593E4 Q33689166-48E6AC8F-5792-43B7-A65F-6179408F8053 Q34087755-5CA825B3-F4C9-4618-A2B9-A207C8AD5D01 Q34562952-E2EDE15A-1875-4706-A889-AB627F79CEC5 Q34660422-AB9FC4F7-C050-4C84-A596-30F296692A1D Q34883543-5B548C61-9D5A-4A1B-8FD2-BF01825CFAF8 Q35033443-485672BF-7315-43F2-ACDD-09BCC2792B88 Q35170821-3DC0A5E1-1914-4BCD-8049-263652AC3E42 Q35214487-AB34DB37-B997-43DF-AD13-4A3CDD2B74F5 Q36026263-5F032639-57B2-4DA2-A98B-47BD7D897BDF Q36053849-4C0AB991-1E73-453C-8CE1-4E80E026606F Q36480147-E661B895-7626-490E-9DA3-F36E0BC2F36F Q36945838-D5EEEE71-E0C9-4C79-B0E5-87292D9E6680 Q37102102-6F594347-E1DF-4328-919B-17B5AC433BC9 Q37274863-1A4EF17E-6293-4E19-AA44-65374576AF18 Q37710341-43E12430-A88B-4703-9BE6-A0040517E439 Q37953796-8A590786-0978-400D-B5A6-282F332870C7 Q38376033-53C42812-9B58-465C-84A4-11361D3AAE59 Q41039072-95D06D06-FAA8-4548-B17A-F290878591E3 Q46125947-E4B3A342-D0E8-4D5E-B343-87636BE4FA45 Q46246286-016C318F-2334-4B41-85A7-B31D0A3723B1 Q47410855-BF2ADE4F-71D6-45DF-A723-64F9B390D029 Q47794110-CD6B26FE-B4FC-4BB1-A751-B2D0FDFC16F7 Q48344793-89101C23-F745-4720-B887-F5905507719D Q55890255-FCD3ADAE-333D-4D8C-BE84-ABD38D6944A8 Q57481187-14C4F319-58A6-4BDF-8AE9-75DFAF713E31 Q57940864-38A231A0-86D4-4C42-9022-7FA503E89B85

P2860

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

http://www.wikidata.org/entity/Q54268700

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@en

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@nl

type

label

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@en

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@nl

prefLabel

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@en

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@nl

P1433

Q54268700-78B181E4-F337-4278-8D14-FFA4CCD253A2

P1476

Q54268700-E88C37ED-58D3-4901-9DFE-00F6D3249660

P2093

Q54268700-274A9012-E9BF-48FC-82F1-D18D8152EBC3

Q54268700-2D88952B-9972-4A89-AA35-1ACDB020A2D9

Q54268700-36573435-9884-4A24-9D07-BA3410C934C0

Q54268700-506E63A3-8725-437A-B476-AA85F8EB7A26

Q54268700-695EE216-4F6E-498C-9F37-56CD73E08109

Q54268700-6BD0EF7F-C73A-459B-B9D6-6ADF9E02C520

Q54268700-73A8463E-EE32-4770-A7E9-3788EB5C7086

Q54268700-7F0BDFC3-1F66-4F87-9C02-B923146F8D53

Q54268700-85B73543-9D65-4C84-BE02-D1FDF74361AB

Q54268700-965264A2-402D-4BEF-A70A-79822E87E8D9

P304

Q54268700-A78D779E-3DFA-4850-B7C6-4845E2E66789

P31

Q54268700-4CDFB8A8-E586-4CE4-BBBE-602952B9E903

P356

Q54268700-391D90D3-D523-485E-A523-0EA35329A585

P407

Q54268700-DE44FB51-DBD4-4848-9424-302C26820E08

P433

Q54268700-58D4AAD8-53BF-47CD-B8B0-630EC20796D5

P478

Q54268700-0D519C22-8213-4A1B-B033-81F1A72CC60E

P50

Q54268700-17F1F3C3-1125-49AE-81D8-174D39F848D0

Q54268700-A6C5ECC5-2FC5-4EF1-BCE9-C66046B9F756

P577

Q54268700-61DFE38A-861A-4BCB-AD3C-BAC5B27E5002

P698

Q54268700-CCF6A9C6-56E9-4032-BD8F-6650A8F0E530

P921

Q54268700-5F60EB14-03D6-46FD-AA26-2CE41B5AAF95

P356

J.VACCINE.2006.09.049

P1433

P1476

Safety and immunogenicity of a ...... ral cholera vaccine in adults.

@en

P2093

Anna Lena Lopez

http://www.w3.org/2001/XMLSchema#string

Dang Duc Anh

http://www.w3.org/2001/XMLSchema#string

Do Gia Canh

http://www.w3.org/2001/XMLSchema#string

Jacqueline Deen

http://www.w3.org/2001/XMLSchema#string

John Clemens

http://www.w3.org/2001/XMLSchema#string

Nguyen Hong Son

http://www.w3.org/2001/XMLSchema#string

Phan Thi Long

http://www.w3.org/2001/XMLSchema#string

Rodney Carbis

http://www.w3.org/2001/XMLSchema#string

Seong Hye Shin

http://www.w3.org/2001/XMLSchema#string

Seung Hyun Han

http://www.w3.org/2001/XMLSchema#string

P304

1149-1155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2006.09.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Lorenz von Seidlein

P577

2006-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17055622

http://www.w3.org/2001/XMLSchema#string

P921